WASHINGTON—Scott Gottlieb, President Donald Trump’s nominee to run the Food and Drug Administration, emphasized in his confirmation hearing Wednesday his belief “in the gold standard of safety and efficacy” at the agency and said he hopes to expand approvals of generic drugs to lower U.S. prices. Dr. Gottlieb, who was nominated in March, said he sees the need for new laws and FDA regulatory action to get complex-formulation drugs—like those used topically or with inhalers—more quickly approved as lower-cost generics....

Source: Wall Street Journal April 05, 2017 18:00 UTC